90 related articles for article (PubMed ID: 1469332)
1. The effects of recombinant human erythropoietin on the cell mediated immune response of renal failure patients.
Singh AB; Singh M; Palekar S; Levy S; Nunn C; Mann RA
J Med; 1992; 23(5):289-302. PubMed ID: 1469332
[TBL] [Abstract][Full Text] [Related]
2. Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy.
Liu JH; Liu YL; Lin HH; Yang YF; Kuo HL; Lin PW; Huang CC
Int J Clin Pract; 2009 Mar; 63(3):387-93. PubMed ID: 18410348
[TBL] [Abstract][Full Text] [Related]
3. [Increased in vitro and ex vivo proliferation of erythroid precursors induced by calcitriol in chronic renal failure. Synergistic effect with rHuEPO].
Aucella F; Gatta G; Vigilante M; Scalzulli RP; Mantuano S; Carotenuto M; Stallone C
G Ital Nefrol; 2002; 19(2):137-42. PubMed ID: 12195411
[TBL] [Abstract][Full Text] [Related]
4. Perturbation of autocrine/paracrine loops of burst-forming units of erythroid-derived cells in rHuEPO-hyporesponsive hemodialysis patients.
Nakao K; Wada J; Ota K; Ichikawa H; Akagi S; Okamoto A; Hida K; Nagake Y; Makino H
Am J Kidney Dis; 2003 Mar; 41(3):624-36. PubMed ID: 12612986
[TBL] [Abstract][Full Text] [Related]
5. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
[TBL] [Abstract][Full Text] [Related]
6. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study).
Benz RL; Pressman MR; Hovick ET; Peterson DD
Am J Kidney Dis; 1999 Dec; 34(6):1089-95. PubMed ID: 10585319
[TBL] [Abstract][Full Text] [Related]
7. Anemia of chronic renal failure: treatment with erythropoietin.
Navarro M; Alonso A; Avilla JM; Espinosa L
Child Nephrol Urol; 1991; 11(3):146-51. PubMed ID: 1777893
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients.
Yamazaki C; Watanabe Y; Sakamoto N
Nihon Jinzo Gakkai Shi; 1993 Nov; 35(11):1233-42. PubMed ID: 8139135
[TBL] [Abstract][Full Text] [Related]
9. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
10. Increased vascular alpha1-adrenergic sensitivity in patients with renal failure: receiving recombinant erythropoeitin.
Abiose AK; Aronow WS; Moreno H; Nair CK; Blaschke TF; Hoffman BB
Am J Ther; 2007; 14(5):427-34. PubMed ID: 17890929
[TBL] [Abstract][Full Text] [Related]
11. Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppression without affecting the distribution of peripheral blood mononuclear cell subpopulations.
Steffensen G; Aunsholt NA; Povlsen JV
Clin Nephrol; 1996 Feb; 45(2):98-103. PubMed ID: 8846537
[TBL] [Abstract][Full Text] [Related]
12. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease.
Holley JL; Nolan TA; Piraino B
Clin Nephrol; 1992 Mar; 37(3):145-7. PubMed ID: 1563119
[TBL] [Abstract][Full Text] [Related]
14. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants.
Meister B; Maurer H; Simma B; Kern H; Ulmer H; Hittmair A; Fink FM
Stem Cells; 1997; 15(5):359-63. PubMed ID: 9323798
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
[TBL] [Abstract][Full Text] [Related]
16. Ca++ and 1,25(OH)2D3 regulate in vitro and in vivo the response to human recombinant erythropoietin in CAPD patients.
Carozzi S; Ramello A; Nasini MG; Schelotto C; Caviglia PM; Cantaluppi A; Salit M; Lamperi S
Adv Perit Dial; 1990; 6():312-5. PubMed ID: 1982836
[TBL] [Abstract][Full Text] [Related]
17. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis.
Berns JS; Rudnick MR; Cohen RM
Clin Nephrol; 1992 May; 37(5):264-7. PubMed ID: 1606777
[TBL] [Abstract][Full Text] [Related]
18. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
19. [Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients].
Caramelo C; Soto C; Neira F; López MD; Jiménez S; Albalate M; de Oña R; Llamas P; Deudero JJ
Nefrologia; 2004; 24(4):351-6. PubMed ID: 15455495
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone and cortisol secretion before and after erythropoietin therapy in CAPD patients.
Diez JJ; Iglesias P; Sastre J; Gomez-Pan A; Mendez J; Bajo MA; Selgas R
Adv Perit Dial; 1994; 10():275-81. PubMed ID: 7999845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
